Erenumab (Aimovig)

1. Overview

Erenumab (marketed as Aimovig) is a fully human immunoglobulin G2 (IgG2) monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor for the preventive treatment of migraine in adults. Approved by the FDA on May 17, 2018, erenumab holds two historic distinctions: it was the first FDA-approved therapy specifically developed to prevent migraine by blocking the CGRP pathway, and the first monoclonal antibody ever approved that targets a G-protein-coupled receptor (GPCR) [6][9].

Erenumab is unique among the four FDA-approved anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) in that it is the only one that blocks the CGRP receptor rather than the CGRP ligand. While fremanezumab, galcanezumab, and eptinezumab bind and sequester the CGRP peptide itself, erenumab directly occupies the ligand-binding site on the CLR/RAMP1 receptor complex, preventing CGRP from activating its downstream signaling cascade [6][7][9].

The antibody has an approximate molecular weight of 150 kDa, comprising two heavy chains (456 amino acids each) and two light chains of the lambda subclass (216 amino acids each). Its suffix "-aooe" in the nonproprietary name erenumab-aooe denotes the distinguishable suffix assigned by the FDA to identify individual biological products. Erenumab has a half-life of approximately 28 days, supporting its monthly subcutaneous dosing regimen of 70 mg or 140 mg, administered via the Amgen SureClick autoinjector or a prefilled syringe [6].

Developed by Amgen (originally designated AMG 334) and commercialized in partnership with Novartis, erenumab was validated across a comprehensive clinical program enrolling more than 3,000 patients in Phase II and Phase III trials (STRIVE, ARISE, LIBERTY, and a chronic migraine Phase II study), demonstrating consistent efficacy in reducing monthly migraine days in both episodic and chronic migraine, including in patients who had failed multiple prior preventive treatments [1][2][3][4].

Type

Fully human IgG2 monoclonal antibody

Molecular Weight

~150 kDa

Target

CGRP receptor (CLR/RAMP1 heterodimer)

Half-life

~28 days

Bioavailability

~82% (subcutaneous)

FDA Approval

May 17, 2018 (first anti-CGRP therapy approved)

Approved Indication

Preventive treatment of migraine in adults

Administration

70 mg or 140 mg SC monthly via SureClick autoinjector or prefilled syringe

Developers

Amgen (originator) / Novartis (global partner)

2. Development History and Regulatory Milestones

Discovery and Preclinical Development

The development of erenumab grew from two decades of basic research linking CGRP to migraine pathophysiology. The pivotal 1990 observation by Goadsby and Edvinsson that CGRP levels were elevated in jugular venous blood during migraine attacks provided the first direct biochemical evidence implicating CGRP in migraine [8]. Subsequent studies demonstrated that intravenous CGRP infusion could trigger migraine-like headaches in susceptible individuals, confirming the peptide as a causal mediator rather than a mere biomarker [9][22].

Amgen initiated development of erenumab (AMG 334) as a fully human monoclonal antibody generated using XenoMouse technology, which produces antibodies with fully human variable and constant regions, eliminating the immunogenicity concerns associated with chimeric or humanized antibodies [6]. The decision to target the CGRP receptor (CLR/RAMP1) rather than the CGRP ligand was a strategic choice that distinguished erenumab from competing antibodies in development. This receptor-targeting approach offered theoretical advantages in completely preventing CGRP-mediated receptor activation regardless of local CGRP concentrations, but also raised the question of whether blocking the receptor at all tissue sites might produce different safety or efficacy profiles compared to ligand-targeting antibodies [6][9].

Amgen-Novartis Partnership

In August 2015, Novartis entered a global collaboration with Amgen to develop and commercialize migraine treatments, including erenumab. The partnership was expanded in April 2017 to include co-commercialization in the United States, with Amgen retaining exclusive commercialization rights in Japan and Novartis holding exclusive rights in Europe, Canada, and the rest of the world [6]. This collaboration was instrumental in accelerating the global clinical development program and enabling rapid post-approval launch.

FDA Approval and Regulatory Timeline

The regulatory path for erenumab proceeded swiftly. Amgen submitted a Biologics License Application (BLA) in July 2017, and the FDA granted approval on May 17, 2018, making Aimovig the first anti-CGRP therapy to reach the market. The approval was based on the combined evidence from three Phase III trials (STRIVE, ARISE, LIBERTY) and a Phase II chronic migraine study involving more than 2,600 patients [1][2][3][4]. The European Medicines Agency (EMA) subsequently approved erenumab in July 2018 under the brand name Aimovig.

Post-approval label updates have included the addition of constipation with serious complications (October 2019) and hypertension (2021) to the Warnings and Precautions section of the prescribing information, reflecting emerging post-marketing safety signals [12][13][14].

3. Mechanism of Action

Targeting the CGRP Receptor Complex

The CGRP receptor is a heterodimeric complex consisting of the calcitonin receptor-like receptor (CLR), a class B GPCR, and receptor activity-modifying protein 1 (RAMP1), a single-transmembrane-domain accessory protein essential for receptor trafficking, ligand binding, and receptor specificity [10][11]. RAMP1 serves dual functions: it chaperones CLR from the endoplasmic reticulum to the plasma membrane, and it contributes directly to the extracellular ligand-binding pocket that confers selectivity for CGRP over other members of the calcitonin peptide family. Without RAMP1, CLR cannot bind CGRP. When CLR associates with RAMP2 instead, it forms the adrenomedullin-1 receptor, and with RAMP3, the adrenomedullin-2 receptor [10][11].

Erenumab binds to the extracellular domain of the CLR/RAMP1 complex with high affinity and specificity. It functions as a competitive antagonist, preventing CGRP from accessing its binding site and thereby blocking downstream receptor activation. Under normal conditions, CGRP binding to CLR/RAMP1 activates the Gs alpha subunit, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP), which activates protein kinase A (PKA) and triggers vasodilation, neurogenic inflammation, and pain signal amplification in the trigeminovascular system [10][22].

Structural Basis of Receptor Blockade

The crystal structure of the erenumab Fab fragment bound to the extracellular domain of the CGRP receptor (PDB: 6UMG), resolved by Garces and colleagues in 2020, revealed the molecular mechanism underlying its antagonism [7]. The key structural feature is erenumab's remarkably long 21-residue complementarity-determining region H3 (CDR-H3) loop, which adopts a distinctive tyrosine-rich helix-turn tip that projects deep into the interface between the CLR and RAMP1 subunits. This CDR-H3 loop directly occupies the pocket in which the C-terminal region of CGRP normally makes high-affinity contacts with the receptor, establishing a primarily orthosteric blocking mechanism [7].

Erenumab engages residues on both CLR and RAMP1 simultaneously, which provides the molecular basis for its exquisite selectivity for the CGRP receptor over structurally related calcitonin family receptors. Pharmacological characterization has demonstrated that erenumab displays approximately 80- to 100-fold selectivity for the CGRP receptor over the AMY1 receptor (formed by the calcitonin receptor paired with RAMP1), and it does not meaningfully antagonize the adrenomedullin or calcitonin receptors at therapeutic concentrations [7][16].

Role of CGRP in Migraine Pathophysiology

CGRP plays a central role in the trigeminovascular system, the neural-vascular interface underlying migraine headache. During a migraine attack, activation of trigeminal sensory neurons triggers CGRP release from both peripheral terminals at meningeal blood vessels and central terminals in the trigeminal nucleus caudalis (TNC). Peripherally, CGRP causes meningeal vasodilation, plasma protein extravasation, and mast cell degranulation, collectively termed neurogenic inflammation. This inflammatory cascade sensitizes nociceptive fibers and lowers the threshold for pain signaling [8][9][22].

Within the trigeminal ganglion, secreted CGRP acts on neighboring neurons and satellite glial cells expressing CLR/RAMP1, creating paracrine signaling loops that amplify and perpetuate pain signals. Centrally, CGRP released at the TNC facilitates synaptic transmission and contributes to central sensitization of second-order nociceptive neurons projecting to the thalamus and cortex [9][22]. By blocking the CGRP receptor, erenumab interrupts this cascade at the receptor level, preventing CGRP-driven neurogenic inflammation, peripheral sensitization, and central pain amplification.

4. Clinical Trials

STRIVE Trial (Phase III, Episodic Migraine)

The STRIVE trial was the pivotal Phase III study that established erenumab's efficacy in episodic migraine [1]. Published in the New England Journal of Medicine in 2017, this randomized, double-blind, placebo-controlled trial enrolled 955 patients with episodic migraine (4 to 14 monthly migraine days) across 121 sites in North America, Europe, and the Asia-Pacific region.

Patients were randomized 1:1:1 to receive subcutaneous erenumab 70 mg, erenumab 140 mg, or placebo every 4 weeks for 24 weeks. The primary endpoint was change from baseline in mean monthly migraine days over months 4 through 6. From a baseline of approximately 8.3 monthly migraine days, erenumab 70 mg and 140 mg reduced monthly migraine days by 3.2 and 3.7 days respectively, compared to 1.8 days for placebo (p-values for both comparisons with placebo were significant) [1].

The 50% responder rate (proportion of patients achieving at least 50% reduction in monthly migraine days) was 43.3% for erenumab 70 mg and 50.0% for erenumab 140 mg, compared to 26.6% for placebo. Both doses also significantly reduced the number of days requiring acute migraine-specific medication. A 52-week open-label extension confirmed sustained efficacy, with no evidence of tolerance or waning effect over time [1][25].

ARISE Trial (Phase III, Episodic Migraine)

The ARISE trial was a confirmatory Phase III study evaluating the 70 mg dose of erenumab in episodic migraine [2]. This randomized, double-blind, placebo-controlled trial enrolled 577 patients who were randomized 1:1 to erenumab 70 mg or placebo every 4 weeks for 12 weeks, with 570 patients included in the efficacy analysis.

Erenumab 70 mg reduced monthly migraine days by 2.9 days compared to 1.8 days for placebo, yielding a treatment difference of -1.0 days (95% CI: -1.6 to -0.5, p=0.001). The 50% responder rate was 39.7% for erenumab versus 29.5% for placebo (p=0.010). Erenumab also significantly reduced monthly migraine-specific medication treatment days by 1.2 days versus 0.6 days for placebo (p=0.002) [2].

The safety profile was consistent with the STRIVE trial, with adverse event rates similar between erenumab and placebo groups. The most common adverse events were upper respiratory tract infection, injection site pain, and nasopharyngitis [2].

LIBERTY Trial (Phase IIIb, Prior Treatment Failures)

The LIBERTY trial addressed a critical clinical question: can erenumab benefit patients who have failed multiple prior preventive treatments? [3]. This Phase IIIb study enrolled 246 patients with episodic migraine who had documented failure (lack of efficacy or intolerance) with 2 to 4 prior migraine preventive medications.

Patients were randomized 1:1 to erenumab 140 mg or placebo monthly for 12 weeks. The primary endpoint was the proportion of patients achieving 50% or greater reduction in monthly migraine days during weeks 9 to 12. Erenumab 140 mg achieved this endpoint in 30.3% of patients compared to 13.7% for placebo (odds ratio 2.73, p=0.002) [3]. This nearly threefold higher odds of meaningful response in a treatment-refractory population was a landmark finding for the anti-CGRP field.

Long-term follow-up from the LIBERTY open-label extension demonstrated sustained efficacy, with 50% or greater responder rates reaching 57.2% at 112 weeks, suggesting that response may improve or consolidate with continued treatment. Two-year data confirmed maintained efficacy and a consistent safety profile [3].

Phase II Chronic Migraine Study

Erenumab's efficacy in chronic migraine (15 or more headache days per month, of which at least 8 are migraine days) was established in a Phase II randomized, double-blind, placebo-controlled trial [4]. This multicenter study enrolled 667 patients randomized to placebo, erenumab 70 mg, or erenumab 140 mg every 4 weeks for 12 weeks.

Both erenumab doses reduced monthly migraine days by 6.6 days from a baseline of approximately 18 days, compared to 4.2 days for placebo (difference -2.5 days, 95% CI: -3.5 to -1.4, p=0.0001 for both doses). Adverse event profiles were similar across groups, with injection site pain, upper respiratory tract infection, and nausea being the most frequently reported events [4].

Long-term Efficacy and Safety (5-Year Extension)

The longest prospective evaluation of erenumab is the 5-year open-label extension of the original Phase II episodic migraine trial [5]. Of 383 patients who entered the extension, 215 (56.1%) completed the full 5-year treatment period. Patients initially received erenumab 70 mg, later increased to 140 mg following a protocol amendment.

At year 5, the mean reduction from a baseline of 8.7 monthly migraine days was 5.3 days, representing a 62.3% reduction sustained over 5 years. Monthly acute migraine-specific medication use decreased by 4.4 days from a baseline of 6.3 days. Patient-reported outcomes demonstrated stable improvements in disability scores, headache impact, and migraine-specific quality of life throughout the 5-year period, with no evidence of efficacy attenuation [5][20]. No new safety signals emerged during long-term treatment, providing important reassurance regarding the sustained tolerability of chronic CGRP receptor blockade.

5. Clinical Evidence Summary

6. Comparison with Other Anti-CGRP Monoclonal Antibodies

Erenumab belongs to a class of four FDA-approved anti-CGRP monoclonal antibodies for migraine prevention, each with distinct pharmacological properties.

| Feature | Erenumab (Aimovig) | Fremanezumab (Ajovy) | Galcanezumab (Emgality) | Eptinezumab (Vyepti) | |---|---|---|---|---| | Target | CGRP receptor (CLR/RAMP1) | CGRP ligand | CGRP ligand | CGRP ligand | | Antibody type | Fully human IgG2 | Humanized IgG2-delta-a | Humanized IgG4 | Humanized IgG1 | | Route | SC (autoinjector/syringe) | SC (autoinjector/syringe) | SC (autoinjector/syringe) | IV infusion | | Dosing frequency | Monthly (70 or 140 mg) | Monthly (225 mg) or quarterly (675 mg) | Monthly (120 mg after 240 mg loading) | Quarterly (100 or 300 mg IV) | | Loading dose | None required | None (quarterly uses 675 mg) | 240 mg (2 x 120 mg injections) | None required | | Half-life | ~28 days | ~31 days | ~27 days | ~27 days | | FDA approval | May 2018 | September 2018 | September 2018 | February 2020 | | Other indications | Migraine only | Migraine only | Migraine + episodic cluster headache | Migraine only |

Efficacy Comparisons

Network meta-analyses and real-world comparative studies suggest that all four anti-CGRP monoclonal antibodies demonstrate broadly comparable efficacy and tolerability in migraine prevention, consistent with a pharmacological class effect [23]. The 50% responder rates in treatment-refractory populations (patients with prior preventive failures) are approximately 30% for erenumab 140 mg (LIBERTY), 34% for fremanezumab (FOCUS), and 38% for galcanezumab 120 mg (CONQUER) [1][3][17][18].

However, some nuanced differences have been reported. In network meta-analyses, erenumab 140 mg appears particularly effective for reducing acute medication use, while fremanezumab and eptinezumab 300 mg may offer a slight advantage in 50% responder rates [23]. Eptinezumab is notable for its rapid onset of effect, with demonstrable efficacy as early as day 1 after IV infusion [19]. Galcanezumab is the only anti-CGRP monoclonal antibody also approved for episodic cluster headache prevention [18].

Receptor-Targeting vs. Ligand-Targeting

The distinction between receptor-targeting (erenumab) and ligand-targeting (fremanezumab, galcanezumab, eptinezumab) approaches has clinical implications. Because erenumab blocks the receptor at all tissue sites, it may produce more complete blockade of CGRP signaling in tissues where receptor density is high. This could contribute to the relatively higher incidence of constipation observed with erenumab compared to ligand-targeting antibodies, since CGRP has motor-stimulating and prosecretory functions in the gastrointestinal tract, and receptor blockade prevents all CGRP isoforms from activating intestinal CGRP receptors [14][23].

Conversely, ligand-targeting antibodies allow residual CGRP receptor activation by other calcitonin family peptides (such as adrenomedullin) that can also interact with CLR/RAMP1 at certain concentrations, potentially preserving some protective signaling. Whether this distinction translates to meaningful clinical differences in cardiovascular or wound-healing outcomes during long-term therapy remains an open question [15][21][23].

Switching between anti-CGRP antibodies is an established clinical practice, and evidence supports that patients who do not respond to one antibody may benefit from switching to another, including switching between receptor-targeting and ligand-targeting approaches [23][24].

7. Episodic vs. Chronic Migraine

Erenumab has demonstrated efficacy in both episodic migraine (4 to 14 migraine days per month) and chronic migraine (15 or more headache days per month, at least 8 being migraine days), though the clinical trial evidence base differs between the two populations.

For episodic migraine, three Phase III trials (STRIVE, ARISE, LIBERTY) and a 5-year open-label extension provide robust evidence of efficacy across diverse patient populations, including treatment-refractory patients [1][2][3][5]. The treatment effect sizes (reduction in monthly migraine days vs. placebo) range from 1.0 to 1.9 days, with 50% responder rates approximately 15 to 25 percentage points higher than placebo.

For chronic migraine, the Phase II study demonstrated a 2.5-day reduction in monthly migraine days beyond placebo, from a higher baseline of approximately 18 days [4]. While no Phase III chronic migraine trial was conducted specifically for erenumab, the 140 mg dose is recommended by clinical guidelines for patients with chronic migraine based on the Phase II data and real-world evidence supporting its use in this population.

The higher absolute baseline in chronic migraine means that the proportional reduction is somewhat lower than in episodic migraine, though the absolute improvement in migraine days is clinically meaningful. Real-world studies suggest that approximately one-third of chronic migraine patients treated with erenumab will achieve a clinically meaningful response within 3 months [4].

8. Administration and Device

Erenumab is administered as a subcutaneous injection using either the Amgen SureClick autoinjector or a prefilled syringe. The 70 mg dose requires a single injection, while the 140 mg dose is given as two consecutive 70 mg injections at different sites or as a single 140 mg injection (available in certain markets).

The SureClick autoinjector was specifically designed for patient self-administration. The device features a spring-loaded mechanism that delivers the injection over approximately 15 seconds. A visible yellow indicator window confirms injection completion. Injection sites include the abdomen, thigh, or upper arm, with rotation recommended between injections. No loading dose is required, which simplifies initiation compared to galcanezumab (which requires a 240 mg loading dose) [6].

The autoinjector should be stored refrigerated at 2 to 8 degrees Celsius and removed 30 minutes before use to reach room temperature. Once removed from refrigeration, it may be stored at room temperature (20 to 25 degrees Celsius) for up to 7 days. The device should not be shaken, exposed to direct sunlight, or frozen [6].

9. Safety Considerations

Constipation

Constipation has emerged as the most clinically significant adverse effect of erenumab. While clinical trial data showed relatively modest rates (1% placebo, 1% erenumab 70 mg, 3% erenumab 140 mg during 12-week double-blind periods), post-marketing experience tells a different story. Real-world surveys indicate that constipation may affect more than 50% of erenumab-treated patients, and FDA Adverse Event Reporting System (FAERS) data show constipation as the second most frequently reported event for erenumab (4.90 per 1,000 exposed patients), dramatically higher than for fremanezumab (0.46) or galcanezumab (0.76) [14].

The mechanism is well-characterized: CGRP stimulates intestinal motility and fluid secretion, and erenumab's receptor blockade abolishes these prosecretory and motor-stimulating functions. The higher constipation rate with erenumab compared to ligand-targeting antibodies is consistent with its receptor-blocking mechanism, which prevents all CGRP isoforms from activating gastrointestinal CGRP receptors [14]. In October 2019, the FDA updated the Aimovig prescribing information to include constipation with serious complications, including cases requiring hospitalization and surgical intervention.

Hypertension

An emerging safety signal involves blood pressure elevation. Clinical trials showed low hypertension rates (0.8% for erenumab 70 mg, 0.2% for erenumab 140 mg vs. 0.9% for placebo) [13]. However, post-marketing case reports identified significant blood pressure elevations, with a median systolic increase of 39 mmHg and median diastolic increase of 28 mmHg in reported cases. Notably, 46% of these events occurred within one week of the first erenumab dose [12][13].

The plausible mechanism involves blockade of CGRP's vasodilatory function. CGRP is the most potent endogenous vasodilator known, and its tonic activity contributes to blood pressure regulation. Blocking the CGRP receptor could remove this compensatory vasodilatory brake, particularly in patients with underlying vascular vulnerability [15]. The FDA updated the erenumab label to include hypertension in the Warnings and Precautions section and recommended blood pressure monitoring in treated patients [12][13].

Cardiovascular Safety

The broader question of cardiovascular safety during long-term CGRP receptor blockade has been extensively debated. Because CGRP serves protective cardiovascular functions including vasodilation, cardioprotection during ischemia-reperfusion, and anti-hypertensive counterregulation, concerns were raised that sustained blockade could increase risk of hypertension, stroke, myocardial infarction, or impaired response to cardiac ischemia [15][21].

Reassuringly, the 5-year open-label extension study showed no new cardiovascular safety signals [5][20]. Claims database studies comparing erenumab to other migraine preventive treatments have not demonstrated increased rates of composite cardiovascular events [13]. However, patients with established cardiovascular disease, uncontrolled hypertension, and cerebrovascular disease were largely excluded from pivotal clinical trials, and vigilance in these populations remains warranted [15][21].

Injection Site Reactions and Other Adverse Effects

Injection site reactions (pain, erythema, pruritus) are common but generally mild and transient. Other reported adverse events include fatigue, nasopharyngitis, and upper respiratory tract infections at rates similar to placebo. Rare cases of hypersensitivity reactions, including angioedema, have been reported in the post-marketing setting [1][2][5].

Erenumab is eliminated via the reticuloendothelial system through proteolytic degradation rather than hepatic CYP450 metabolism, which confers the practical advantage of no known drug-drug interactions. This distinguishes erenumab and the other anti-CGRP monoclonal antibodies from the gepant class, which are CYP3A4 substrates with potential for pharmacokinetic interactions [6].

10. Pharmacokinetics: Anti-CGRP Monoclonal Antibody Comparison

The pharmacokinetic profiles of the four approved anti-CGRP monoclonal antibodies differ meaningfully in ways that influence dosing strategy, onset of action, and clinical decision-making.

| PK Parameter | Erenumab (Aimovig) | Fremanezumab (Ajovy) | Galcanezumab (Emgality) | Eptinezumab (Vyepti) | |---|---|---|---|---| | Route | SC | SC | SC | IV | | Bioavailability | ~82% | ~55% | ~65% | 100% (IV) | | Tmax | 4-6 days | 5-7 days | 5-7 days | ~1.5 hours (end of infusion) | | Half-life | ~28 days | ~31 days | ~27 days | ~27 days | | Steady state | ~12 weeks (3 doses) | ~6 months (quarterly) or ~5 months (monthly) | ~5 months | By 3rd quarterly dose | | Volume of distribution | 3.86 L | 5.3 L | 7.3 L | 3.86 L | | Clearance | 0.11 L/day | 0.09 L/day | 0.008 L/hr | 0.15 L/day | | Immunogenicity (ADA) | ~6.2% (neutralizing ~1%) | ~0.4% | ~12.5% (neutralizing ~1.6%) | ~15-20% (neutralizing ~6.2%) | | PK linearity | Linear at 70-140 mg (TMDD at lower doses) | Linear across clinical range | Linear at 120-240 mg | Linear at 100-300 mg | | Food/body weight effect | No clinically significant effect | No clinically significant effect | No clinically significant effect | Not applicable (IV) | | Drug interactions | None (no CYP450 metabolism) | None (no CYP450 metabolism) | None (no CYP450 metabolism) | None (no CYP450 metabolism) |

Key pharmacokinetic distinctions with clinical relevance include the following. Eptinezumab, administered intravenously, achieves 100% bioavailability and therapeutic plasma concentrations within hours, explaining its documented efficacy as early as day 1 post-infusion -- a property no subcutaneous antibody can match [19]. Fremanezumab's longer half-life (~31 days) and lower clearance support its unique quarterly dosing option at 675 mg. Erenumab demonstrates target-mediated drug disposition (TMDD) at doses below 70 mg, where receptor binding contributes meaningfully to clearance; at the approved 70 mg and 140 mg doses, receptor saturation is achieved and pharmacokinetics are linear [6]. All four antibodies are eliminated via the reticuloendothelial system through proteolytic degradation rather than CYP450-mediated hepatic metabolism, which confers the practical advantage of no drug-drug interactions -- a meaningful distinction from the gepant class (rimegepant, ubrogepant, atogepant), which are CYP3A4 substrates.

11. Dose-Response: 70 mg vs 140 mg Erenumab

The dose-response relationship between erenumab 70 mg and 140 mg has been a central question in clinical practice. The STRIVE trial provided the most robust head-to-head dose comparison, and additional data from the chronic migraine Phase II study, LIBERTY, and long-term extension studies have refined the clinical picture.

| Endpoint | Erenumab 70 mg | Erenumab 140 mg | Placebo | |---|---|---|---| | STRIVE: Change in MMD (months 4-6) | -3.2 days | -3.7 days | -1.8 days | | STRIVE: 50% responder rate | 43.3% | 50.0% | 26.6% | | STRIVE: 75% responder rate | 18.8% | 23.5% | 12.0% | | STRIVE: Acute med days reduction | -1.1 days | -1.6 days | -0.2 days | | ARISE: Change in MMD (12 weeks) | -2.9 days | Not tested | -1.8 days | | Chronic migraine Phase II: Change in MMD | -6.6 days | -6.6 days | -4.2 days | | LIBERTY (treatment failures): 50% responder | Not tested | 30.3% | 13.7% |

The 140 mg dose consistently produces numerically greater responses across efficacy measures, with the most notable separation in the 50% responder rate (50.0% vs 43.3% in STRIVE) and the 75% responder rate. For chronic migraine, the two doses appeared equivalent in the Phase II study, though only 140 mg was tested in the treatment-refractory LIBERTY population [1][3][4]. Clinical guidelines generally recommend initiating with 70 mg and escalating to 140 mg if response is suboptimal after 3 months, while starting at 140 mg may be preferred in patients with chronic migraine, high baseline migraine frequency, or prior preventive treatment failures.

Pharmacokinetic modeling suggests that the dose-response plateau begins to flatten at 140 mg, with receptor occupancy exceeding 90% at both doses. The incremental benefit of 140 mg over 70 mg likely reflects more complete receptor saturation at peripheral tissue sites with lower antibody penetration, such as the dura and trigeminal ganglion, rather than a simple concentration-response relationship [6].

12. Comparative Effectiveness: Anti-CGRP mAbs and Gepants

Anti-CGRP Monoclonal Antibodies: Network Meta-Analysis Findings

Network meta-analyses synthesizing data across pivotal trials of all four anti-CGRP monoclonal antibodies have consistently found broadly comparable efficacy, supporting a pharmacological class effect, while identifying nuanced differences [23]:

| Outcome | Erenumab 140 mg | Fremanezumab 225 mg/mo | Galcanezumab 120 mg/mo | Eptinezumab 300 mg/qtr | |---|---|---|---|---| | 50% responder rate (episodic) | 50.0% (STRIVE) | 47.7% (HALO-EM) | 62.3% (EVOLVE-1) | 49.8% (PROMISE-1) | | 50% responder rate (treatment-refractory) | 30.3% (LIBERTY) | 34% (FOCUS) | 38% (CONQUER) | Not specifically tested | | Mean MMD reduction (episodic) | -3.7 days | -3.7 days | -4.7 days | -3.9 days | | Onset of action | Significant by month 1 | Significant by month 1 | Significant by month 1 | Significant by day 1 | | Acute medication reduction | -1.6 days (STRIVE) | -1.4 days (HALO-EM) | -1.6 days (EVOLVE-1) | -1.8 days (PROMISE-1) |

Direct comparisons across trials are limited by differences in trial design, patient populations, and outcome definitions. However, several patterns emerge: galcanezumab 120 mg has shown the highest numerical 50% responder rates in both general and treatment-refractory episodic migraine populations; eptinezumab 300 mg offers the fastest onset due to IV administration; erenumab 140 mg and fremanezumab demonstrate similar overall efficacy with different practical advantages (erenumab's simple monthly dosing vs fremanezumab's quarterly option) [17][18][19][23].

Comparison with Gepants (CGRP Receptor Antagonists)

The gepant class (small-molecule CGRP receptor antagonists) now includes agents approved for both acute and preventive migraine treatment, creating an important comparison with anti-CGRP monoclonal antibodies:

| Feature | Anti-CGRP mAbs (erenumab etc.) | Preventive Gepants (atogepant, rimegepant) | |---|---|---| | Mechanism | Antibody blocks CGRP receptor (erenumab) or ligand | Small molecule blocks CGRP receptor | | Administration | SC injection monthly/quarterly or IV quarterly | Oral daily (atogepant) or every-other-day (rimegepant) | | Half-life | 27-31 days | 11 hours (atogepant), 11 hours (rimegepant) | | Drug interactions | None | CYP3A4 substrates (dose adjustments with strong inhibitors/inducers) | | Hepatic safety | No hepatotoxicity signal | Rare transaminase elevations (class monitoring) | | Constipation rate | Higher with erenumab (receptor blockade) | Lower | | Onset | Full effect by month 3 (steady state) | Rapid onset (within days to weeks) | | Switching | Non-responders may benefit from mAb-to-gepant switch | Gepant non-responders may respond to mAbs | | 50% responder (episodic) | 43-62% depending on agent | 55.6% (atogepant 60 mg, ADVANCE trial) | | Dual use | Prevention only | Rimegepant: acute + preventive in single agent |

The choice between monoclonal antibodies and gepants involves trade-offs between dosing convenience (monthly/quarterly injection vs daily oral), drug interaction potential (none for mAbs vs CYP3A4 considerations for gepants), and patient preference. Switching between mAbs and gepants is supported by clinical experience showing that non-responders to one class may respond to the other, likely reflecting pharmacokinetic and pharmacodynamic differences in receptor occupancy patterns [23][24].

13. Enhanced Safety Profile

Comprehensive Adverse Event Comparison Across Anti-CGRP Therapies

| Adverse Event | Erenumab 70 mg | Erenumab 140 mg | Fremanezumab | Galcanezumab | Eptinezumab | |---|---|---|---|---|---| | Constipation | 1-3% (trials); ~50% (real-world) | 3-4% (trials); ~50% (real-world) | 0.5-1% | 0.5-1% | 0.5% | | Injection site reactions | 3-6% | 3-6% | 17-45% | 8-18% | N/A (IV) | | Nasopharyngitis/URTI | 4-6% | 4-6% | 3-5% | 5-8% | 6-10% | | Hypertension | 0.2-0.8% (trials); higher post-marketing | 0.2-0.8% (trials); higher post-marketing | Not a significant signal | Not a significant signal | Not a significant signal | | Infusion/hypersensitivity | Rare angioedema | Rare angioedema | Rare | Rare | 1-2% (IV infusion reactions) | | Fatigue | 3-4% | 3-4% | 3-5% | 2-4% | 1-2% | | Nausea | 1-2% | 1-2% | 1-2% | 1-2% | 1-2% | | Serious AE rate | ~2% | ~2% | ~2% | ~2% | ~2% |

Constipation Risk Stratification

The disproportionately higher constipation rate with erenumab compared to ligand-targeting antibodies warrants specific risk management [14]:

Risk factors for severe constipation with erenumab:

• Pre-existing constipation or IBS-C
• Concurrent opioid or anticholinergic use
• Elderly patients with reduced GI motility
• Erenumab 140 mg (higher rate than 70 mg)

Management approach:

• Screen for baseline bowel habits before initiation
• Provide anticipatory guidance regarding constipation
• Recommend prophylactic stool softeners or osmotic laxatives in at-risk patients
• Consider switching to a ligand-targeting anti-CGRP antibody if constipation is intolerable
• FDA added constipation with serious complications (including hospitalization and surgery) to prescribing information in October 2019

Hypertension Monitoring Protocol

Based on post-marketing surveillance data, the following monitoring approach is recommended [12][13]:

• Measure blood pressure at baseline before first injection
• Recheck blood pressure within 1-2 weeks of the first dose (46% of post-marketing hypertension cases occurred within the first week)
• Monitor at each subsequent injection visit
• Patients with pre-existing hypertension may require antihypertensive medication adjustment
• Median blood pressure elevations in reported cases: systolic +39 mmHg, diastolic +28 mmHg
• Consider discontinuation if clinically significant hypertension develops and does not respond to treatment

Long-Term Safety Reassurance

The 5-year open-label extension data provide the most comprehensive long-term safety assessment for any anti-CGRP therapy [5][20]:

• No new safety signals emerged over 5 years of continuous treatment
• No evidence of immunological complications from sustained CGRP receptor blockade
• Anti-drug antibody rates remained stable and did not affect efficacy
• No cardiovascular events attributable to chronic CGRP blockade
• No evidence of rebound headache upon treatment discontinuation in extension studies
• Sustained efficacy without tachyphylaxis (no dose escalation needed)

Ongoing post-marketing surveillance continues to monitor for potential long-term consequences of sustained CGRP pathway blockade, including cardiovascular outcomes in high-risk populations, wound healing effects, and reproductive outcomes, though no concerning signals have emerged to date [15][21].

March 2025 FDA Class-Wide Safety Labeling Update

In March 2025, the FDA updated the prescribing information for all CGRP monoclonal antibodies and gepants to include warnings regarding the potential for developing or worsening pre-existing hypertension and Raynaud's phenomenon. For erenumab specifically, constipation was also formally added to the class-wide labeling. Regarding Raynaud's phenomenon, post-marketing reports identified cases with a median symptom onset of 71 days after dosing, with many cases involving serious outcomes including hospitalization and disability due to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in symptom resolution. Clinicians are advised to monitor patients for new-onset hypertension, worsening of pre-existing hypertension, and signs of Raynaud's phenomenon during treatment with any CGRP-targeting therapy.

14. Molecular and Pharmacological Details

Erenumab is a fully human IgG2 monoclonal antibody with an approximate molecular weight of 150 kDa. It consists of two identical heavy chains (456 amino acids each) and two identical lambda light chains (216 amino acids each), connected by interchain disulfide bonds. The IgG2 isotype was selected for its reduced effector function compared to IgG1 or IgG3, minimizing the potential for Fc-mediated immune activation such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) [6].

The pharmacokinetic profile of erenumab is characteristic of monoclonal antibodies: bioavailability is approximately 82% following subcutaneous administration, with a time to maximum plasma concentration (Tmax) of 4 to 6 days. The elimination half-life is approximately 28 days, supporting once-monthly dosing. Steady-state concentrations are achieved after approximately 12 weeks (3 doses) of monthly administration. Erenumab demonstrates nonlinear pharmacokinetics at doses below 70 mg due to target-mediated drug disposition, but exhibits linear pharmacokinetics at the approved doses of 70 mg and 140 mg, where receptor saturation is achieved [6].

Anti-drug antibodies (ADAs) were detected in approximately 6% of patients in clinical trials, with neutralizing antibodies in approximately 1%. The presence of ADAs did not appear to affect efficacy or safety in clinical studies, and the fully human nature of the antibody minimizes immunogenicity risk compared to chimeric or humanized constructs [5][6].

15. Related Peptides

See also: CGRP (Calcitonin Gene-Related Peptide), Calcitonin, Amylin (IAPP), Adrenomedullin

16. References

1. [1] Goadsby PJ, Reuter U, Hallstrom Y, et al. (2017). A controlled trial of erenumab for episodic migraine (STRIVE). New England Journal of Medicine. DOI PubMed
2. [2] Dodick DW, Ashina M, Brandes JL, et al. (2018). ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. DOI PubMed
3. [3] Reuter U, Goadsby PJ, Lanteri-Minet M, et al. (2018). Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study (LIBERTY). The Lancet. DOI PubMed
4. [4] Tepper S, Ashina M, Reuter U, et al. (2017). Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology. DOI PubMed
5. [5] Ashina M, Kudrow D, Reuter U, et al. (2021). Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. European Journal of Neurology. DOI PubMed
6. [6] Shi L, Lehto SG, Bhatt DK, et al. (2020). Discovery of the migraine prevention therapeutic Aimovig (erenumab), the first FDA-approved antibody against a G-protein-coupled receptor. ACS Pharmacology and Translational Science. DOI PubMed
7. [7] Garces F, Mohr C, Zhang L, et al. (2020). Molecular insight into recognition of the CGRPR complex by migraine prevention therapy Aimovig (erenumab). Cell Reports. DOI PubMed
8. [8] Goadsby PJ, Edvinsson L, Ekman R. (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology. DOI PubMed
9. [9] Edvinsson L, Haanes KA, Warfvinge K, Krause DN. (2018). CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nature Reviews Neurology. DOI PubMed
10. [10] Russell FA, King R, Smillie SJ, Kodji X, Brain SD. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. Physiological Reviews. DOI PubMed
11. [11] Hay DL, Walker CS. (2017). CGRP and its receptors. Headache. DOI PubMed
12. [12] Saely S, Croteau D, Bhatt DK, et al. (2021). Hypertension: a new safety risk for patients treated with erenumab. Headache. DOI PubMed
13. [13] Dodick DW, Gottschalk C, Engel ER, et al. (2021). Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. Headache. DOI PubMed
14. [14] Rubio-Beltran E, Chan KY, et al. (2022). Constipation caused by anti-CGRP migraine therapeutics explained by antagonism of CGRP's motor-stimulating and prosecretory function in the intestine. Frontiers in Physiology. DOI PubMed
15. [15] MaassenVanDenBrink A, Meijer J, Villalon CM, Ferrari MD. (2016). Wiping out CGRP: potential cardiovascular risks. Trends in Pharmacological Sciences. DOI PubMed
16. [16] Garelja ML, Walker CS, Hay DL. (2024). Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors. British Journal of Pharmacology. DOI PubMed
17. [17] Silberstein SD, Dodick DW, Bigal ME, et al. (2017). Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine. DOI PubMed
18. [18] Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. (2018). Evaluation of galcanezumab for the prevention of episodic migraine (EVOLVE-1). JAMA Neurology. DOI PubMed
19. [19] Ashina M, Saper J, Cady R, et al. (2020). Eptinezumab in episodic migraine (PROMISE-1). Cephalalgia. DOI PubMed
20. [20] Ashina M, Goadsby PJ, Reuter U, et al. (2019). Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. DOI PubMed
21. [21] Deen M, Correnti E, Kamm K, et al. (2017). Blocking CGRP in migraine patients - a review of pros and cons. The Journal of Headache and Pain. DOI PubMed
22. [22] Iyengar S, Ossipov MH, Johnson KW. (2017). The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. DOI PubMed
23. [23] Romozzi M, Caraci C, et al. (2025). Pharmacological differences and switching among anti-CGRP monoclonal antibodies: a narrative review. Headache. DOI PubMed
24. [24] Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. (2019). Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. The Journal of Headache and Pain. DOI PubMed
25. [25] Goadsby PJ, Reuter U, Hallstrom Y, et al. (2020). One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology. DOI PubMed